Vimpat

RSS

lacosamide

Authorised
This medicine is authorised for use in the European Union.

Overview

This is a summary of the European public assessment report (EPAR) for Vimpat. It explains how the Agency assessed the medicine to recommend its authorisation and its conditions of use. It is not intended to provide practical advice on how to use Vimpat.

For practical information about using Vimpat, patients should read the package leaflet or contact their doctor or pharmacist.

This EPAR was last updated on 05/09/2019

Authorisation details

Product details
Name
Vimpat
Agency product number
EMEA/H/C/000863
Active substance
lacosamide
International non-proprietary name (INN) or common name
lacosamide
Therapeutic area (MeSH)
Epilepsy
Anatomical therapeutic chemical (ATC) code
N03AX18
Publication details
Marketing-authorisation holder
UCB Pharma SA
Revision
30
Date of issue of marketing authorisation valid throughout the European Union
29/08/2008
Contact address
Allée de la Recherche 60
BE-1070 Brussels
Belgium

Product information

31/07/2019 Vimpat - EMEA/H/C/000863 - II/0073/G

Contents

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

Anti epileptics

Therapeutic indication

Vimpat is indicated as monotherapy and adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy.

Assessment history

Changes since initial authorisation of medicine

How useful was this page?

Add your rating
Average
1 rating